Survey: Only 29% of patients screened for oral cancer

Survey: Only 29% of patients screened for oral cancer March 31, 2017 Only 29% of U.S. patients reported being screened for oral cancer at their last visit to the dental office, according to a new survey released by the Oral Cancer Foundation, the Head and Neck Cancer Alliance, Vigilant Biosciences, and Support for People with Oral

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are March 30, 2017 Fort Lauderdale, Fla. Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck

Vigilant spearheads oral cancer survey to gauge patient awareness

Vigilant spearheads oral cancer survey to gauge patient awareness March 30, 2017 According to a recent survey conducted by Vigilant Biosciences in collaboration with the Oral Cancer Foundation, Head and Neck Cancer Alliance, and Support for People with Oral and Head and Neck Cancer, more than 60% of consumers know very little or nothing about oral cancer—a disease that nearly 50,000 people are

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups March 30, 2017 According to a national survey released today, the majority (62 percent) of adults in the U.S. know very little, or nothing at all, about oral (including cancer of the oral cavity, tongue, larynx

Oral Cancer Tests Capture Biomarkers Using Saline Rinse

Oral Cancer Tests Capture Biomarkers Using Saline Rinse March 27, 2017 The OncAlert oral cancer product line from Vigilant Biosciences Inc, Fort Lauderdale, Fla, is now available in select markets. The company’s OncAlert oral cancer product line includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting the

Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert™ Oral Cancer and OncAlert Labs Product Lines

Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert™ Oral Cancer and OncAlert Labs Product Lines March 22, 2017 Fort Lauderdale, Fla. Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the acceptance of five abstracts regarding data related to studies

Vigilant Biosciences to Showcase OncAlert™ Oral Cancer Product Line at International Dental Show 2017

Vigilant Biosciences to Showcase OncAlert™ Oral Cancer Product Line at International Dental Show 2017 March 20, 2017 Fort Lauderdale, Fla. and Cologne, Germany OncAlert RAPID Test aids in the early detection and intervention of oral cancer; fits seamlessly into dental practice standard of care Vigilant Biosciences, Inc., a leading innovator and developer of solutions that

Vigilant Biosciences Announces Poster Presentation on Multivariate Oral Rinse Models for Prediction of Head and Neck Squamous Cell Carcinoma at the 6th International Conference on Innovative Approaches in Head and Neck Oncology

Vigilant Biosciences Announces Poster Presentation on Multivariate Oral Rinse Models for Prediction of Head and Neck Squamous Cell Carcinoma at the 6th International Conference on Innovative Approaches in Head and Neck Oncology March 15, 2017 Fort Lauderdale, Fla. and Barcelona, Spain Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev C